The New York-based biopharmaceutical company said that the preliminary results were observed from the first six subjects enrolled in the open-label trial dubbed NCT02226146. Immune Pharmaceuticals stated that
The phase 3 clinical trial dubbed as MINDSET featured 1,315 patients with mild to moderate Alzheimer's disease who were on donepezil therapy over 24 weeks. Intepirdine taken orally
The new company has been launched with a $103m Series A financing. Initially, SpringWorks will work on potential programs for four rare diseases – desmoid tumor, neurofibromatosis, hereditary xerocytosis
The new JV firm will focus on the use of nanolipogel (NLG) technology, which was developed by researchers from Yale University. The technology will enable to encapsulate different
The two companies have entered into a clinical research collaboration in this regard to assess the therapeutic regimen in NSCLC and potentially other advanced solid tumors in the
Bavencio, which is intended to be delivered intravenously, is a human antibody designed to inhibit the programmed death ligand-1 (PD-L1) protein. It has been developed to potentially engage
Gazyvaro is an engineered monoclonal antibody proposed to attach to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells. It is
Rydapt has been approved to be used for the hard-to-treat cancers in combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy. The drug has been
The FDA has approved fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or Trelegy Ellipta as a long-term, once-daily and maintenance treatment for patients with COPD, including chronic bronchitis and emphysema. Trelegy Ellipta
The New Jersey-based drug contract manufacturer will pay $750m at the time of closing of the transaction. It will pay the remainder amount in interest-free equal installments over
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.